|
Synonyms: AMG 104 | AMG104 | AZD-8630 | AZD8630
Compound class:
Antibody
Comment: Sunakiment (AMG 104, formerly AZD-8630) is an anti-thymic stromal lymphopoietin (TSLP) antigen-binding fragment (Fab) class antibody. It prevents TSLP interaction with its receptor, thereby blocking TSLP-mediated signalling responses. Peptide sequences for the heavy and light chain variable regoins of sunakiment match those of antibody A5 as claimed in patent US7982016 [1].
|
| No information available. |
Summary of Clinical Use ![]() |
| Sunakiment was progressed to clinical studies as a potential inhalation therapy for moderate-to-severe asthma. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05110976 | A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists | Phase 1 Interventional | AstraZeneca | First-in-human study | 2 |
| NCT06529419 | A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations | Phase 2 Interventional | AstraZeneca | ||